US 12,337,017 B2
Microbiota transfer therapy for Pitt Hopkins Syndrome
James Adams, Tempe, AZ (US); Rosa Krajmalnik-Brown, Chandler, AZ (US); and Audrey Davidow, Studio City, CA (US)
Assigned to Arizona Board of Regents on Behalf of Arizona State University, Tempe, AZ (US); and Pitt Hopkins Research Foundation, Winston-Salem, NC (US)
Appl. No. 17/604,972
Filed by Arizona Board of Regents, Tempe, AZ (US)
PCT Filed Apr. 20, 2020, PCT No. PCT/US2020/028997
§ 371(c)(1), (2) Date Oct. 19, 2021,
PCT Pub. No. WO2020/215080, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/836,404, filed on Apr. 19, 2019.
Prior Publication US 2022/0211771 A1, Jul. 7, 2022
Int. Cl. A61K 35/74 (2015.01); A61P 25/28 (2006.01)
CPC A61K 35/74 (2013.01) [A61P 25/28 (2018.01)] 19 Claims
 
1. A method for treating Pitt Hopkins syndrome (PTHS) in a subject in need thereof, comprising
administering to the subject a fecal microbe preparation comprising at least 1×109 cells for at least 12 weeks, thereby reducing severity of PTHS symptoms in the subject by at least 10% as determined by a clinical global impression scale applied to the subject before and after the treatment.